| Literature DB >> 22022172 |
Shruti S Shiromwar1, Vijay R Chidrawar.
Abstract
BACKGROUND: Doxorubicin (DOX) is the most active cytotoxic agents having efficacy in malignancies either alone or combined with other cytocidal agents. The clinical usefulness of the anthracycline drug has been precluded by cardiac toxicity. Many therapeutic interventions have been attempted to improve the therapeutic benefits of the drug. This study is based on the possible protective effects of combination of p-coumaric acid (PC) and naringenin (NR) on DOX induced cardiac toxicity in male Swiss albino rats.Entities:
Keywords: Antioxidents; cardiotoxicity; doxorubicine; naringenin; p-coumaric acid
Year: 2011 PMID: 22022172 PMCID: PMC3193624 DOI: 10.4103/0974-8490.85012
Source DB: PubMed Journal: Pharmacognosy Res ISSN: 0974-8490
Treatment schedule-number of groups with their treatment schedule is presented
Figure 1The effects of combination of drug, i.e. p-coumaric acid and naringenin on heart SOD, CAT, GSH, thiobarbituric acid reactive substance (TBARS), in normal and doxorubicin (DOX)-induced myocardial infarction in Swiss albino rats. DOX = Doxorubicin, PC = p-coumaric acid, Vit = Vitamin, NR = Naringenin. *P < 0.05 is less significant as compared to Group I; **P < 0.01 is signifi cant as compared to Group I; +P < 0.05 is less signifi cant as compared to Group II; ++P < 0.01 signifi cant as compared to Group II. Comparison between experimental and control groups were performed by ANOVA followed by Dunnett's test for post hoc comparison, when appropriate.